The Emerging Go-to-Market Strategy for AI/ML Healthcare Innovation
Whether driven by regulatory, reimbursement, policy, or investment tailwinds, 2026 is poised to be a pivotal year for healthcare innovation leveraging artificial intelligence and machine learning (AI/ML). This whitepaper examines why, despite this increasing regulatory flexibility for certain AI applications, pursuing FDA authorization and product-specific coding, coverage, and reimbursement can remain a highly attractive commercial path – and in some use cases, the most durable route to long-term scale.
